A PYMNTS Company

Mylan Loses Bid To dismiss EpiPen Antitrust Suit

By  |  January 17, 2021

Mylan and a group of pharmacy benefit managers have lost a bid to dismiss a class action claiming the drugmaker paid kickbacks to the PBMs in order to drive up the price of its anti-allergy injection EpiPen, a federal judge has ruled.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    US District Judge Eric Tostrud in Minnesota ruled Friday, January 15, that the plaintiffs, a group of drug distributors, had successfully pleaded their case that Mylan, Optum, CVS Caremark, and Express Scripts engaged in a conspiracy under the Racketeer Influenced and Corrupt Organizations Act, and that Mylan violated the Sherman Act.

    The suit filed in Trenton, New Jersey, Sanofi claimed that Mylan caused it to lose hundreds of millions of dollars in sales by erecting barriers to US consumers’ access to and use of a rival product, Auvi-Q.

    In particular, Sanofi claimed that Mylan offered rebates to insurers, pharmaceutical benefit managers and state Medicaid agencies conditioned on Auvi-Q not being an epinephrine auto-injector device they would reimburse for use by consumers.

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.